参考文献/References:
[1].Barbato E,Azizi M,Schmieder RE,et al. Renal denervation in the management of hypertension in adults. A clinical consensus statement of the ESC Council on Hypertension and the European Association of Percutaneous Cardiovascular Interventions (EAPCI)[J]. Eur Heart J,2023,44(15):1313-1330.
[2].Kario K,Kim BK,Aoki J,et al. Renal denervation in Asia:Consensus Statement of the Asia Renal Denervation Consortium[J]. Hypertension,2020,75(3):590-602.
[3].李月平,卢成志,蒋雄京,等. 经皮去肾神经术治疗高血压中国专家科学声明[J]. 中国介入心脏病学杂志,2023,31(12):881-893.
[4].Mahfoud F,Schlaich MP,Lobo MD. Device therapy of hypertension[J].?Circ Res,2021,128(7):1080-1099.
[5].Lauder L,Azizi M,Kirtane AJ,et al. Device-based therapies for arterial hypertension[J].?Nat Rev Cardiol,2020,17(10):614-628.
[6].Townsend RR,Mahfoud F,Kandzari DE,et al,Catheter-based renal denervation in patients with uncontrolled hypertension in the absence of antihypertensive medications (SPYRAL HTN-OFF MED):a randomised,sham-controlled,proof-of-concept trial[J]. Lancet,2017,11,390(10108):2160-2170.
[7].Mahfoud F,Kandzari DE,Kario K,et al. Long-term efficacy and safety of renal denervation in the presence of antihypertensive drugs (SPYRAL HTN-ON MED):a randomised,sham-controlled trial[J]. Lancet,2022,399(10333):1401-1410.
[8].B?hm M,Kario K,Kandzari DE,et al. Efficacy of catheter-based renal denervation in the absence of antihypertensive medications (SPYRAL HTN-OFF MED Pivotal) :a multicentre,randomised,sham-controlled trial[J]. Lancet,2020,395(10234):1444-1451.
[9].Mahfoud F,B?hm M,Schmieder R,et al. Effects of renal denervation on kidney function and long-term outcomes:3-year follow-up from the Global SYMPLICITY Registry[J]. Eur Heart J,2019,40(42):3474-3482.
[10].Wang J,Yin Y,Lu C,et al. Efficacy and safety of sympathetic mapping and ablation of renal nerves for the treatment of hypertension (SMART):6-month follow-up of a randomised,controlled trial[J]. EClinicalMedicine,2024,72:102626.
[11].Krum H,Schlaich M,Whitbourn R,et al. Catheter-based renal sympathetic denervation for resistant hypertension:a multicentre safety and proof-of-principle cohort study[J]. Lancet,2009,373(9671):1275-1281.
[12].Esler MD,Krum H,Schlaich M,et al. Renal sympathetic denervation for treatment of drug-resistant hypertension:one-year results from the Symplicity HTN-2 randomized,controlled trial[J]. Circulation,2012,126(25):2976-2982.
[13].Bakris GL,Townsend RR,Flack JM,et al. 12-month blood pressure results of catheter-based renal artery denervation for resistant hypertension:the SYMPLICITY HTN-3 trial[J]. J Am Coll Cardiol,2015,65(13):1314-1321.
[14].Singh RR,McArdle ZM,Iudica M,et al. Sustained decrease in blood pressure and reduced anatomical and functional reinnervation of renal nerves in hypertensive sheep 30 months after catheter-based renal denervation[J]. Hypertension,2019,73(3):718-727.
[15].Sharp ASP,Tunev S,Schlaich M,et al. Histological evidence supporting the durability of successful radiofrequency renal denervation in a normotensive porcine model[J]. J Hypertens,2022,40(10):2068-2075.
[16].Azizi M,Schmieder RE,Mahfoud F,et al. Endovascular ultrasound renal denervation to treat hypertension (RADIANCE-HTN SOLO) :a multicentre,international,single-blind,randomised,sham-controlled trial[J]. Lancet,2018, 391(10137):2335- 2345.
[17].Azizi M,Sanghvi K,Saxena M,et al. Ultrasound renal denervation for hypertension resistant to a triple medication pill (RADIANCE-HTN TRIO):a randomised,multicentre,single-blind,sham-controlled trial[J]. Lancet,2021,397(10293):2476-2486.
[18].Rader F,Kirtane AJ,Wang Y,et al. Durability of blood pressure reduction after ultrasound renal denervation:three-year follow-up of the treatment arm of the randomised RADIANCE-HTN SOLO trial[J]. EuroIntervention,2022,18(8):e677-e685.
[19].Azizi M,Saxena M,Wang Y,et al. Endovascular ultrasound renal denervation to treat hypertension :The RADIANCE II Randomized Clinical trial[J]. JAMA,2023,329(8):651-661.
[20].Kario K,Yokoi Y,Okamura K,et al. Catheter-based ultrasound renal denervation in patients with resistant hypertension:the randomized,controlled REQUIRE trial[J]. Hypertens Res,2022,45(2):221-231.
[21].Mathiassen ON,Vase H,Bech JN,et al. Renal denervation in treatment-resistant essential hypertension. A randomized,SHAM-controlled,double-blinded 24-h blood pressure-based trial[J]. J Hypertens,2016,34(8):1639-1647.
[22].Schmieder RE,Ott C,Toennes SW,et al. Phase II randomized sham-controlled study of renal denervation for individuals with uncontrolled hypertension-WAVE IV[J]. J Hypertens,2018,36(3):680-689.
[23].Mahfoud F,Renkin J,Sievert H,et al. Alcohol-mediated renal denervation using the Peregrine System Infusion Catheter for treatment of hypertension[J]. JACC Cardiovasc Interv,2020, 13 (4):471-484.
[24].Kandzari DE,Weber MA,Pathak A,et al. Effect of alcohol-mediated renal denervation on blood pressure in the presence of antihypertensive medications:primary results from the TARGET BP I Randomized Clinical Trial[J]. Circulation,2024,149(24):1875-1884.
[25].Ji M,Chen H,Shen L,et al.Validation of a novel renal denervation system with cryoablation:a preclinical study and case series[J]. JACC Basic Transl Sci,2022,7(2):101-112.
[26].Liu Z,Shen L,Huang W,et al. Efficacy and safety of renal denervation for Chinese patients with resistant hypertension using a microirrigated catheter:study design and protocol for a prospective multicentre randomised controlled trial[J]. BMJ Open,2017,7(9):e015672.
相似文献/References:
[1]李昱熙 张震 余静 蒋雄京.去肾神经治疗高血压的临床前景和探索方向[J].心血管病学进展,2024,(10):865.[doi:10.16806/j.cnki.issn.1004-3934.2024.10.001]
LI YuxiZHANG ZhenYU JingJIANG Xiongjing.Future of Renal Denervation on Hypertension Therapy[J].Advances in Cardiovascular Diseases,2024,(10):865.[doi:10.16806/j.cnki.issn.1004-3934.2024.10.001]
[2]陈晓平,左祥浩,叶涛,等.当前经导管去肾神经术治疗高血压面临的挑战[J].心血管病学进展,2024,(10):870.[doi:10.16806/j.cnki.issn.1004-3934.2024.10.002]
CHEN Xiaoping,ZUO Xianghao,YE Tao,et al.Current Challenges of Transcatheter Renal Denervation in the Treatment of Hypertension[J].Advances in Cardiovascular Diseases,2024,(10):870.[doi:10.16806/j.cnki.issn.1004-3934.2024.10.002]
[3]王沛坚 陈威 董徽 马为.中国自主研发RDN器械治疗高血压临床试验数据的特色[J].心血管病学进展,2024,(10):880.[doi:10.16806/j.cnki.issn.1004-3934.2024.10.004]
WANG Peijian,CHEN Wei,DONG Hui,et al.Characteristics of Clinical Trial Data of RDN Devices Independently Developed in China[J].Advances in Cardiovascular Diseases,2024,(10):880.[doi:10.16806/j.cnki.issn.1004-3934.2024.10.004]
[4]封欣妤 张冬颖 邹玉宝 冯颖青 程康.如何选择去肾神经术治疗高血压的最适宜人群[J].心血管病学进展,2024,(10):885.[doi:10.16806/j.cnki.issn.1004-3934.2024.10.005]
FENG Xinyu,ZHANG Dongying,ZOU Yubao,et al.How to Select the Optimal Population for Renal Denervation in the Treatment of Hypertension[J].Advances in Cardiovascular Diseases,2024,(10):885.[doi:10.16806/j.cnki.issn.1004-3934.2024.10.005]
[5]董一飞 张毅 李燕 贾楠.经皮去肾神经术治疗高血压的临床获益：证据和争议[J].心血管病学进展,2024,(10):890.[doi:10.16806/j.cnki.issn.1004-3934.2024.10.006]
DONG Yifei,ZHANG Yi,LI Yan,et al.Clinical Benefit of Renal Denervation In the Treatment of Hypertension:Evidence And Controversy[J].Advances in Cardiovascular Diseases,2024,(10):890.[doi:10.16806/j.cnki.issn.1004-3934.2024.10.006]